Accession Number : ADA586254


Title :   Disparities in Intratumoral Steroidogenesis


Descriptive Note : Annual rept. 15 Jun 2012-14 Jun 1013


Corporate Author : CHILDREN'S HOSPITAL CORP BOSTON MA


Personal Author(s) : Solomon, Keith R ; Pelton, Kristine


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a586254.pdf


Report Date : Jul 2013


Pagination or Media Count : 34


Abstract : Prostatic adenocarcinoma (PC) is the most common form of non-cutaneous cancer and second most lethal cancer in American men but demonstrates tremendous disparity in both incidence and severity between African American men (AAM) and Caucasian men (CM). We have identified prostatic intratumoral steroidogenesis as a biological factor that may explain some or much of the disparity in lethal PC rates between AAM and CM. We proposed testing this hypothesis by examining intratumoral steroidogenesis in the prostates of men following radical prostatectomy and in vivo model systems. In this project period we have finished our initial round of in vivo modeling and have demonstrated that hypercholesterolemia contributes to prostate tumor growth in our model mimicking the human patient situation in which androgen deprivation therapy (castration) is applied after tumor initiation. End point testing is currently underway and we anticipate finding excess androgen and nuclear AR in tumors undergoing relapse in hypercholesterolemic mice. Blinded analysis is ongoing and will be unblinded as soon as all end point data has been collected. The final data are anticipated to reveal that, as hypothesized, hypercholesterolemia contributes to faster relapse after castration and increases intratumoral steroidogenesis.


Descriptors :   *PROSTATE CANCER , *STEROIDS , AFRICAN AMERICANS , ANDROGENS , CAUCASIANS , DEPRIVATION , GROWTH(PHYSIOLOGY) , HYPERCHOLESTEROLEMIA , HYPOTHESES , IN VIVO ANALYSIS , LETHALITY , NEOPLASMS , PATIENTS , PROSTATE GLAND , TEST AND EVALUATION , TESTES


Subject Categories : Biochemistry
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE